Pricing Log in Create free account
Saturday 17 October 2026 Export ZTEKF’s income statement to Excel — free account

Zentek Ltd.

ZTEKF Healthcare Medical Instruments & Supplies

Zentek Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $120,200.00, down 80.8% from fiscal 2025. In the quarter to June 2026, revenue fell 95.4%, EPS was flat, free cash flow fell 254.6% and total debt rose 6.53%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.39 0.04 −9.30%
Market cap
$62.3M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
1/9
Altman Z
−2.15
Beneish M
n/a
Dividend safety
n/a
Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 62.30
Revenue 0.12
Net Income (7.56)
Free Cash Flow (4.56)
Net Debt (10.68)
Current Ratio 4.65 (at or above 1.5: strong)
Debt/Equity 0.07 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E —
P/S ratio 374.43 (above 10: high)
P/B ratio 2.47
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth —
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 288×, against a ten-year median of 412×; over the ten years it ranged from −721× in 2023 to 4,124× in 2024.
P/S against its own 10 years 27.28%
10-year low 10-year high
P/B against its own 10 years 35.57%
10-year low 10-year high
EV/Sales against its own 10 years 26.02%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 3 0 1 12
Receivables 0 1 0 0
Inventory 1 1 0 0
Other — — — —
5 3 2 13
2024 2025 2026 Q'26
Payables 1 2 2 3
ST’ Debt 0 0 — —
Other — — — —
1 3 3 3

Compound Annual Growth %

10y 5y 3y
Sales — — 29.69%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (8.03%) (19.37%) (32.42%)

Revenue $m

Jun Sep Dec Mar Year
’26 — — — — —
’26 0 0 0 0 0
’25 0 0 0 1 1
’24 — 0 0 0 0
’23 0 — 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 (1) — — — —
’26 (1) (1) (1) (1) (4)
’25 (1) (1) (1) (1) (5)
’24 (1) (2) (1) (1) (6)
’23 (2) (3) (2) (2) (10)
’22 (1) (2) (2) (2) (6)
’21 0 0 (1) 0 (1)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 (1) — — — —
’26 1 (1) (2) (1) (2)
’25 (1) (1) (1) (1) (5)
’24 (1) (2) (1) (1) (6)
’23 (3) (3) (2) (3) (12)
’22 (1) (2) (3) (4) (10)
’21 0 (1) (1) (1) (2)
Fiscal quarters ending in the months shown.

EPS $

Jun Sep Dec Mar Year
’26 (0.01) — — — —
’26 (0.01) (0.02) (0.01) (0.03) (0.07)
’25 (0.02) (0.02) (0.01) (0.01) (0.07)
’24 (0.02) (0.02) (0.02) (0.02) (0.09)
’23 (0.04) (0.03) (0.02) (0.01) (0.11)
’22 (0.02) (0.26) (0.02) (0.04) (0.34)
’21 0.00 0.00 (0.02) (0.02) (0.04)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 0.46 0.27 0.21 0.17 1.36 1.28 0.97 0.50 0.62 0.37

Analyst estimates 2027–2029

Powerpack
High 0.93 0.65 0.47 2.94 5.95 4.12 1.80 1.59 1.84 1.10
People
People Employees — — — — — 25 29 24 17 10
Revenue/emp, $m — — — — — 0.01 0.00 0.00 0.04 0.01
Income, $m
Income, $m Revenue — — — — — 0 0 0 1 0
Gross margin, % 0.00 0.00 0.00 0.00 0.00 (8.52) (1,071.51) (1,010.41) 22.02 (1,018.89)
EBT (2) (1) (2) (1) (3) (31) (11) (9) (7) (7)
EBT margin, % 0.00 0.00 0.00 0.00 0.00 (11,144.44) (19,790.20) (39,258.82) (1,150.61) (5,881.86)
Net income (2) (1) (2) (1) (3) (10) (11) (9) (7) (7)
Depreciation 0 0 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00
Earnings (0.04) (0.02) (0.03) (0.02) (0.04) (0.34) (0.11) (0.09) (0.07) (0.07)
Cash flow (0.02) (0.01) (0.01) (0.01) (0.02) (0.07) (0.10) (0.06) (0.04) (0.03)
Capex (0.01) (0.01) (0.02) (0.02) (0.01) (0.03) (0.02) 0.00 0.00 0.01
Free cash flow (0.03) (0.02) (0.03) (0.03) (0.03) (0.10) (0.11) (0.06) (0.05) (0.02)
Book value 0.28 0.27 0.28 0.25 0.25 0.30 0.22 0.15 0.10 0.07
Shares, m 62 63 67 77 84 92 103 101 103 106
Valuation, ×
Valuation, × P/E — — — — — 0.00 0.00 0.00 0.00 0.00
P/S — — — — — 0.00 0.00 4,297.12 182.31 467.03
P/B — — — — — 10.19 6.85 8.13 10.78 7.91
EV/Sales — — — — — 0.00 (662.34) 4,233.47 182.75 471.81
EV/FCF — — — — — (27.36) (13.09) (18.72) (24.65) (23.04)
Cash, $m
Cash, $m Operating cash flow (1) (1) (1) (1) (1) (6) (10) (6) (5) (4)
Capex (1) 0 (1) (1) (1) (3) (2) 0 0 1
Free cash flow (2) (1) (2) (2) (2) (10) (12) (6) (5) (2)
Balance, $m
Balance, $m Working capital 1 0 1 0 1 24 12 3 1 (1)
Total debt — — — — 0 2 1 1 0 1
Net debt (1) 0 (1) (1) (2) (20) (7) (2) 0 0
Shareholders’ equity 17 17 19 19 21 28 23 15 11 7
Returns, %
Returns, % ROA (12.79) (7.03) (10.06) (5.91) (13.75) (115.99) (39.30) (41.39) (48.16) (58.57)
ROIC (8.19) (4.66) (6.52) (4.21) (10.90) (78.87) (43.50) (43.68) (39.66) (66.94)
ROE (12.85) (7.07) (10.23) (6.05) (14.61) (127.62) (43.14) (45.74) (56.47) (79.91)
Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Mar 2026

Charts ten years each

Zentek Ltd. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NYXH Nyxoah SA $121.2M — (loss-making) — (loss-making) +486.62% (above 0%: growing) n/m +4.01% (above 0%: growing) 59.73% (268.25%) Compare
STXS Stereotaxis Inc. $105.2M — (loss-making) — (loss-making) −12.82% (below 0%: shrinking) n/m +0.45% (above 0%: growing) 58.49% (59.56%) Compare
MBOT Microbot Medical Inc. $63.8M — (loss-making) — +1,047.62% (above 0%: growing) n/m −98.72% (below 0%: shrinking) (266.80%) (2,567.63%) Compare
ZTEKF Zentek Ltd. $62.3M — (loss-making) — −95.36% (below 0%: shrinking) n/m −254.61% (below 0%: shrinking) 0.00% 0.00%
DXR Daxor Corporation $59.6M 4.7× 7.6× −27.62% (below 0%: shrinking) n/m −88.56% (below 0%: shrinking) 0.00% 0.00% Compare
POCI Precision Optics Corp. $47.7M — (loss-making) — +41.95% (above 0%: growing) n/m −45.64% (below 0%: shrinking) 25.34% (1.21%) Compare
NEPH Nephros Inc. $38.1M 23.4× 76.0× +36.16% (above 0%: growing) +450.00% (above 0%: growing) −31.49% (below 0%: shrinking) 66.91% 20.16% Compare
HBIO Harvard Bioscience, Inc. $37.8M — (loss-making) — (loss-making) +11.13% (above 0%: growing) n/m −123.43% (below 0%: shrinking) 55.57% (4.30%) Compare
MLSS Milestone Scientific, Inc. $29.6M — (loss-making) — (loss-making) +22.27% (above 0%: growing) n/m +66.68% (above 0%: growing) 67.24% (37.37%) Compare
Median of peers $53.7M — — +29.22% — −38.56% 57.03% (20.83%)

All 55 Medical Instruments & Supplies stocks →

Zentek Ltd. (ZTEKF) key facts

  • Concern: Zentek Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $120,200.00, down 80.8% from fiscal 2025.
  • Zentek Ltd. (ZTEKF) is a Medical Instruments & Supplies company in the Healthcare sector.
  • As of October 16, 2026, ZTEKF traded at $0.39, a market capitalization of $62.3 million.
  • Return on equity was −79.9% and debt-to-equity 0.07.
  • Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −2.15 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.

Zentek Ltd. (ZTEKF) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ZTEKF · Data as of Mar 31, 2026 · For information only; not investment advice. · © 2026 stockrow.com